Bus - API is critical. I had similar analysis and also feel it’s not possible and sustainable to support the “1 out of 3 or 4” patient population with fish EPA.
IMO, algae is the future for Vascepa. Amarin or whoever owns Vascepa needs to invest heavily in algal EPA. Someone here posted today about this. Nannochloropsis is well known in algae research field to produce high content EPA. So if Vascepa is approved and sales start flying, we will see startups and accelerated innovations in this area.
There is precedent case for this. Search Martech Biosciences, now part of DSM. Martech “perfected” manufacturing omega 3 with high DHA content from algae. It used to dominate the infant formulae market as many formula products are fortified with DHA. Some milk we see in supermarket also are fortified with DHA. I won’t be surprised some of them use algae sourced DHA.